A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number
4020-01-001

To Learn More Call
201-510-0910

A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
201-510-0910

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Incyte

Protocol Number
INCB 39110-107

To Learn More Call
201-510-0910

An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-101-02

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Moderna

Protocol Number
mRNA-4157-P101

To Learn More Call
201-510-0910

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Tesaro

Protocol Number